Neumora Therapeutics (NMRA) Long-Term Debt Issuances (2025)
Neumora Therapeutics (NMRA) posted quarterly Long-Term Debt Issuances of $38.9 million for Q4 2025, up 28702.21% quarter-over-quarter from -$136000.0 in Q3 2025.
Neumora Therapeutics (NMRA) Long-Term Debt Issuances (2025) Analysis & Trends
Neumora Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $38.9 million for Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $38.9 million; the TTM figure through Dec 2025 stood at $38.8 million (changed N/A YoY), while the FY2025 annual figure was $57.2 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2025 stood at $38.9 million, up from -$136000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $38.9 million in Q4 2025, with the low at -$136000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 38.90 Mn |
| Dec 31, 2025 | 38.90 Mn |
| Sep 30, 2025 | -136,000.00 |
| Sep 30, 2025 | -136,000.00 |